tbuckley/cabot-search huggingface dataset:
Organophosphorus pesticides directly simulate macrophages to increase expression of growth factors and cytokines
Authors: Becky Proskocil, Pamela Lein, David Jacoby, Allison Fyer
Journal: European Respiratory Journal (2014)

A single s.c. injection of the organophosphorus pesticides (OPs) parathion, chlorpyrifos, or diazinon causes airway hyperreactivity and neuronal M2 muscarinic receptor dysfunction in guinea pigs 24 hr later. OP-induced airway hyperreactivity is dependent on tumor necrosis factor α (TNFα) but independent of interleukin-1β (IL-1β) or inhibition of acetylcholinesterase (AChE) (Proskocil BJ et al., Am J Physiol Lung Cell Mol Physiol. 2013; 304:L519-29). We tested whether OPs and their oxon metabolites directly stimulate human macrophages to increase expression of factors that modulate neuronal M2 receptors. THP1 cells, a human monocyte cell line differentiated into macrophage-like cells, were treated with 1-100 μM parathion, chlorpyrifos, or diazinon or 1-100 nM paraoxon, chlorpyrifos oxon, or diazoxon for 24 hr. mRNA was measured by real-time PCR and released proteins were analyzed by ELISA. None of the OPs or oxons affected cell viability. Parathion, chlorpyrifos, and diazinon increased mRNA expression of TNFα, IL-1β, platelet derived growth factor (PDGF), and transforming growth factor β (TGFβ) in a concentration-dependent manner. TNFα protein was significantly increased at 100 μM, however IL-1β and PDGF proteins were not increased and fibroblast growth factor (FGF) and TGFβ proteins were undetectable. No oxon metabolite increased mRNA or protein levels of these factors. Thus, the parent compounds, but not the oxon metabolites, directly stimulate THP-1 TNFα protein and RNA expression of factors known to modulate M2 muscarinic receptors. These data correlate with our in vivo data demonstrating that OP-induced airway hyperreactivity occurs independent of AChE inhibition.
Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis
Authors: Mitul Gandhi, Adam M. Petrich, Ryan D. Cassaday, Oliver W. Press, Khushboo Shah, Jeremy Whyman, Frederick Lansigan, Andrew D. Zelenetz, Namrata Shah, Timothy S. Fenske, Francisco J. Hernandez-Ilizaliturri, Lisa X. Lee, Stefan K Barta, Reem Karmali, Shruthi Melinamani, Camille Adeimy, Scott E. Smith, Julie M Vose, Neil Dalal, Chadi Nabhan, David Peace, Borko Jovanvoic, Aliyah R. Sohani, Andrew M Evens, Jorge J Castillo, Jeremy S. Abramson
Journal: Blood (2013)
How to Use a Medical Library: A Guide to Research for Practitioners, Research Workers and Students
Authors: Leslie T. Morton
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VEGF kinoid vaccine, a therapeutic arm against tumor angiogenesis and metastases
Authors: E. Ritsou, H. Le Buanec, F. Haghighi Rad, P. Larcier, D. Zagury, G. Uzan
Journal: Journal of Clinical Oncology (2007)

3018 Background: Vascular endothelial growth factor (VEGF) plays a central role in neoangiogenesis and thus represents an important therapeutic target in antiangiogenic cancer therapy strategies. We have developed an anti-VEGF vaccine VEGF kinoid that elicits high titres of neutralizing anti-VEGF antibodies in mice. In this study we have evaluated the immunogenicity, safety and efficacy of VEGF kinoid in preventing tumor growth and metastases in mice. Methods: The efficacy of VEGF kinoid was evaluated in a model of active immunization (CT26 colon carcicoma lung metastases model) and in two models of passive immunization. On the passive immunization setting two VEGF secreting xenograft tumor models, A673 rhabdomyosarcoma and HT29 colon carcinoma, were used to evaluate the ability of IgGs derived from kinoid immunized mice to inhibit tumor growth in comparison with bevacizumab. Results: Active immunization with autologous VEGF Kinoid (mVEGF kinoid) triggered a strong anti-VEGF antibody but no cellular immune response in mice. The anti-VEGF Abs exhibited high neutralizing capacity as assessed via inhibition of human umbilical vein endothelial cell proliferation in the presence of VEGF and binding to the Flk-1 receptor. In mVEGF kinoid immunized BALB/c mice challenged with syngeneic CT26 colorectal tumor cells the lung metastases were inhibited. In human VEGF (hVEGF) kinoid immunized Balb/c mice neutralizing anti-hVEGF Abs were elicited. Purified IgG from these mice inhibited tumor growth of human A673 rhabdomyosarcoma and HT29 colon carcinoma cells xenografted in Swiss nude and NOD/SCID mice respectively as assessed by T/C% measurements. Tumor cell growth inhibition was similar to that in mice receiving therapeutic doses of bevacizumab. Active immunization against VEGF showed an excellent safety profile in mice and no impairment of would healing processes was observed after surgical interventions in immunized mice. Conclusions: These experiments show that active immunization with VEGF kinoid elicits polyclonal neutralizing anti-VEGF Abs that inhibit metastases and tumor growth in mice. It may thus represent an alternative strategy to safely combat VEGF-dependent neovascularization and metastases occurring in malignant tumors. No significant financial relationships to disclose.
Lessons on the Eye. For the Use of Undergraduate Students.
Authors: Frank Laramore Henderson
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Further Studies on Decrementless Conduction.
Authors: 元一 加藤
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The European Medicines Evaluation Agency: open to criticism
Authors: K. Abbasi, A. Herxheimer
Journal: BMJ (1998)

The European Medicines Evaluation Agency has been in existence since 1995 and has authorised the marketing of 62 drugs in the European Union.1 Now fully operational, the agency has furthered its ambition of transparency by starting a public dialogue with the International Society of Drug Bulletins. Rather than quell fears about the agency's activities, however, a recent meeting of the two bodies in London raised a further set of questions about both transparency and rigour.

Although the licensing decisions of national bodies like the Medicines Control Agency in the United Kingdom remain secretive, the European Medicines Evaluation Agency produces a European public assessment report, which attempts to increase openness by outlining the reasons for each licensing decision.2 Concerns, however, surround the rigour of the agency's appraisal of applications for drug licences and the extent to which it is prepared to withhold information from the public that it has been persuaded to treat as …
Increased hepatic iron stores in non alcoholic steatohepatitis (NASH) are associated with the Cys282Tyr hemochromatosis mutation and increased hepatic fibrosis
Authors: G. A. Macdonald, D. K. George, S. Goldwurm, L. L. Cowley, N. I. Walker, P. J. Ward, E. C. Jazwinska, L. W. Powell
Journal: Hepatology (1997)
Urine and the Urinary Sediment: A Practical Manual and Atlas.
Authors: Richard W. Lippman
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 19498: Co-administration of Atorvastatin Prevents Nitroglycerin-induced Endothelial Dysfunction and Nitrate Tolerance in Humans in vivo
Authors: Andrew Liuni, Mary Clare Luca, Giuseppe Di Stolfo, Amar Uxa, Justin A Mariani, Tommaso Gori, John D Parker
Journal: Circulation (2010)

Background: Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against nitroglycerin (GTN)-induced endothelial dysfunctio...
Gene expression differences between disseminated tumor cells and tumor cells from overt bone metastases in patients with metastatic breast cancer
Authors: R. J. Broom, E. Amir, T. Cawthorn, O. Freedman, D. Gianfelice, D. Barth, J. Galica, D. Wang, S. J. Done, M. Clemons
Journal: Journal of Clinical Oncology (2009)

1040 Background: Despite extensive work evaluating molecular differences between primary tumors, circulating tumor cells, disseminated tumor cells (DTCs) and established metastases, it is not apparent which genetic alterations are required to form viable, independent bone metastases (BM). A major limitation in exploring the genetic differences between DTCs and established BM is the paucity of fresh BM tissue available. Methods: Ten breast cancer patients with BM underwent a CT-guided BM biopsy and a bone marrow aspiration (for DTCs). Tumor cells were enriched by immunomagnetic separation and RNA was extracted from each sample. Gene expression profiling was conducted using Illumina Human Ref-8 bead arrays. Microarray data was analyzed using BeadStudio software to identify differentially expressed genes. Ingenuity Pathway Analysis software was used to identify genes integral to specific pathways involved in tumor dissemination. Results: The yield of analyzable malignant cells from BM and bone marrow aspirates was 60% and 80%, respectively. A signature of 133 genes was identified that was differentially expressed between the two sample types. Paired analysis of samples from the same patients identified a subset of 161 genes, of which 52 overlapped with the initial unmatched signature. Several genes relevant to breast cancer metastasis to bone (i.e., osteopontin, CTGF, parathyroid hormone receptor, EGFR) were significantly over-expressed in the BM compared to the DTCs. Conclusions: Results suggest that there are specific subsets of genes, which are required for DTCs in the bone marrow to form overt BM. A number of genes identified are already known to participate in osteolytic BM formation. This signature may allow identification of patients at increased risk for developing BM. No significant financial relationships to disclose.
Abstract 2783: Myocardial Perfusion SPECT with CT Attenuation Correction: Role of Misregistration and Value of Reregistration
Authors: Sibyll Goetze, Tracy L Brown, William C Lavely, Zhe Zhang, Frank M Bengel
Journal: Circulation (2006)

Objective: The accuracy of myocardial perfusion SPECT imaging is improved with attenuation correction (AC). Algorithms using X-ray from a hybrid SPECT/CT system have the potential for misregistrati...
Sémiologie oculaire, le cristallin, Anatomie. Physiologie. Pathologie.
Authors: Félix. Terrien
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Status and Well-Being of the Elderly: National Health and Nutrition Examination Survey-I Epidemiologic Follow-up Study
Authors: Joan Cornoni-Huntley, Robert R. Huntley, Jacob J. Feldman
Journal: Annals of Internal Medicine (1991)

Introduction PART I: STUDY DESIGN AND IMPLEMENTATION: Helen E. Barbano, Bruce B. Cohen, Joel C. Kleinman, Jennifer H. Madans, Jacob J. Feldman, & Joan C. Cornoni-Huntley: Objectives, design and implementation Jennifer H. Madans, Joel C. Kleinman, Christine S. Cox, & Fanchon F. Finucane: Effectiveness of field operations: data collections and tracing PART II: THE ASSOCIATION OF RISK FACTORS WITH MORBIDITY AND MORTALITY FROM SPECIFIC DISEASES: Andrea Z. LaCroix, Steven Lipson, & Lon R. White: Infectious diseases Paul E. Leaverton, Richard J. Havlik, & Lillian Ingster-Moore: Coronary heart disease Arthur S. Scatzkin, D. Yvonne Jones, Tamara B. Harris, Phillip R. Taylor, Robert N. Hoover, Christine L. Carter, Regina G. Ziegler, & Louise A. Brinton: Cancer Lon R. White, Katalin G. Losonczy, & Philip A. Wolf: Cerebrovascular disease Reva C. Lawrence, Donald F. Everett, & Marc C. Hochberg: Arthritis PART III: MORBIDITY AND MORTALITY ASSOCIATED WITH SOCIAL AND PERSONAL CHARACTERISTICS: Diane M. Makuc, Jacob J. Feldman, Joel C. Kleinman, & Mitchel B. Pierre, Jr.: Socio-demographic differences Mary C. Dufour, James D. Colliver, M. Beth Grigson, & Frederick S. Stinson: Use of alcohol and tobacco Suzanne P. Murphy, Donald F. Everett, & Connie M. Dresser: Dietary patterns Paul T. Costa Jr., Robert R. McCrae, & Ben Z. Locke: Personality variables Daniel J. Foley, Laurence G. Branch, Jennifer H. Madans, Dwight B. Brock, Jack M. Guralnik, & T. Franklin Williams: Physical functioning.
Competitive Swimming and Diving
Authors: David Alvin Armbruster
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Introduction to the Microtechnique of Inorganic Analysis
Authors: A. A. Benedetti-Pichler
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4556: Incidence and Mechanisms of Acute and Late Stent Malapposition After Stent Implantation in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the HORIZONS-AMI Trial
Authors: Ning Guo, Akiko Maehara, Gary S Mintz, Alexandra J Lansky, Bernhard Witzenbichler, Giulio Guagliumi, Bruce Brodie, Mirle A Kellett, Helen Parise, Roxana Mehran, Gregg W Stone
Journal: Circulation (2009)

Background. The incidence and mechanisms of stent malapposition (SM) after primary stent implantation in ST-segment elevation myocardial infarction (STEMI) have not been described. Methods. HORIZON...
Abstract 4380: Transition from IV Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic Pulmonary Arterial Hypertension
Authors: LE Melnick, RJ Barst, CA Rowan, Diane Kerstein, D Brady, EB Rosenzweig
Journal: Circulation (2008)

Introduction : Prior to the availability of oral/inhaled (inh) PAH drugs, i.e. 2001–2007, IV epoprostenol (EPO) was the only approved drug for pts un-responsive to calcium channel blockade (CCB). We report our experience transitioning selected pediatric IPAH pts from EPO (initiated prior to 2001) to oral/inh PAH drugs. Methods : We retrospectively reviewed all pediatric IPAH pts treated at Columbia Univ (1991–2008) who transitioned off EPO to oral/inh drugs. Pre-specified criteria for transition included: functional class (FC) I/II, mPAP&lt;35mmHg, normal CO and age &gt; 6 yrs at transition. Hemodynamic and exercise data were obtained at baseline (prior to EPO initiation), at peak EPO dose, and at least 2 mos after EPO discontinuation (d/c) on stable oral/inh drug doses. Data: m ± SD. Results : 13 IPAH pts (6 F) transitioned off EPO between 4/03–11/07 (max dose 100 ± 42ng/kg/min) to oral/inh drugs at 11.6 ± 3.6 yrs of age. Mean duration on EPO: 6.6 ± 3.4yrs (range 1.2–12yrs); f/u post EPO d/c: 10.4 ± 11.6 mos (range 2–42.8 mos). Treatment with EPO improved hemodynamics vs. baseline (p&lt;0.05) with no significant changes in hemodynamics or exercise capacity off EPO. In addition, further improvement was reported in FC off EPO (p&lt;0.002; n=13). Conclusions : In selected IPAH children who began EPO prior to the availability of oral/inh PAH drugs, transition to oral/inh PAH therapy appears safe with efficacy maintained. Whether early initiation of EPO improves long-term outcome vs. deferral of EPO until oral/inh therapy fails remains unknown; further studies with longer-term follow-up are warranted.